Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q1 FY19 results · Apr–Jun 2018
Marksans Pharma reported revenue from operations of ₹235.25 crore and net profit of ₹24.88 crore for Q1 FY19 (Apr–Jun 2018), on a consolidated basis.
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 235.25 | — | — | — | — |
| Other income | 3.23 | — | — | — | — |
| Total income | 238.49 | — | — | — | — |
| Profit before tax | 30.36 | — | — | — | — |
| Net profit for the period | 24.88 | — | — | — | — |
| EPS, basic (₹) | 0.58 | — | — | — | — |
| Net margin (%) | 10.6 | — | — |
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 93.14 | — | — | — | — |
| Other income | 3.22 | — | — | — | — |
| Total income | 96.36 | — | — | — | — |
| Profit before tax | 16.68 | — | — | — | — |
| Net profit for the period | 13.87 | — | — | — | — |
| EPS, basic (₹) | 0.34 | — | — | — | — |
| Net margin (%) | 14.9 | — | — |
Consolidated
- Filed with BSE
- 06 Aug 2018, 16:28 IST
- Board meeting
- 06 Aug 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Aug 2018, 16:28 IST
- Board meeting
- 06 Aug 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE